IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg Television
ImmunoPrecise Antibodies Ltd. (IPATF) announced that CEO Dr. Jennifer Bath will appear on Bloomberg Technology on Sept. 28, 2020, to discuss the company's anti-COVID-19 initiatives, including its innovative Polytope™ Therapy and Vaccines. IPA claims to have developed the world's most comprehensive antibody cocktail program aimed at providing long-lasting protection against COVID-19 and its mutations. The company leverages advanced technologies to support therapy development efficiently.
- Launch of comprehensive anti-COVID-19 programs, including Polytope™ Therapy.
- Development of what is claimed to be the world's most diverse global antibody cocktail program.
- Forward-looking statements warn of risks, including potential lower-than-anticipated revenues and earnings.
VICTORIA, BC, Sept. 28, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO of IPA, is scheduled to appear today as a guest on Bloomberg Technology with host Emily Chang at approximately 5:10 p.m. ET.
Dr. Bath will discuss the Company's comprehensive anti-COVID-19 programs - its Polytope™ Therapy and Vaccines strategies. IPA believes it has launched the most comprehensive and diverse global antibody cocktail program in the world, which, unlike current approaches, is designed to provide durable, long-lasting protection for the entire population and potential mutations.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company's experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise's full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend", "should" and similar expressions to identify forward-looking statements and include the Company's beliefs with respect to the potential for its antibodies to be further developed or approved to treat COVID-19 (or SARS-CoV-2) or to complete any transactions with respect to those antibodies. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the previous quarter ended April 30, 2020 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies
View original content:http://www.prnewswire.com/news-releases/ipa-ceo-dr-jennifer-bath-to-appear-live-today-on-bloomberg-television-301139097.html
SOURCE ImmunoPrecise Antibodies Ltd.
FAQ
What did ImmunoPrecise Antibodies announce on September 28, 2020?
What is the focus of ImmunoPrecise Antibodies' anti-COVID-19 program?
What does IPA claim about its antibody cocktail program?
What are the risks highlighted in ImmunoPrecise's press release?
